{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:01:29Z","timestamp":1791450089157,"version":"4.3.3"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer (US)"},{"name":"Brain-Lab AG"},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["5-30,073"],"award-info":[{"award-number":["5-30,073"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chicago Tumor Institute Center for Radiation Therapy"},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["P30 CA14599"],"award-info":[{"award-number":["P30 CA14599"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0195149","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T13:41:31Z","timestamp":1523540491000},"page":"e0195149","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":114,"title":["Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5172-6889","authenticated-orcid":true,"given":"Julian C.","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diandra N.","family":"Ayala-Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. William","family":"Blackstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Okunieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max W.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph R.","family":"Weichselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Urbanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Chmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1200\/JCO.1994.12.10.2229","article-title":"Karnofsky Memorial Lecture. Natural history of small breast cancers","volume":"12","author":"S Hellman","year":"1994","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"S Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"U Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/JCO.1997.15.3.938","article-title":"Liver resection for colorectal metastases","volume":"15","author":"Y Fong","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma","volume":"34","author":"DR Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"A Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"JM Herman","year":"2015","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"CR King","year":"2013","journal-title":"Radiother Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"JY Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2016.05.004","article-title":"Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases","volume":"6","author":"HA Al-Hallaq","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"ref11","article-title":"Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of &gt;1000 Radiation Oncologists","author":"SL Lewis","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e36979","DOI":"10.1371\/journal.pone.0036979","article-title":"Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases","volume":"7","author":"CCL Tong","year":"2012","journal-title":"PLoS ONE"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cncr.24412","article-title":"Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response","volume":"115","author":"J Kao","year":"2009","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study","volume":"83","author":"MT Milano","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/cncr.26611","article-title":"Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease","volume":"118","author":"JK Salama","year":"2012","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdt537","article-title":"Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival","volume":"25","author":"T de Vin","year":"2014","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"M H\u00f8yer","year":"2006","journal-title":"Acta Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"MT Milano","year":"2008","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"KE Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases","volume":"27","author":"KE Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"C Collen","year":"2014","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer","volume":"32","author":"P Iyengar","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2014.55.9567","article-title":"Radical irradiation of extracranial oligometastases","volume":"32","author":"JK Salama","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.14694\/EdBook_AM.2015.35.e8","article-title":"Surgery or ablative radiotherapy for breast cancer oligometastases","volume":"35","author":"JK Salama","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"AC Wong","year":"2016","journal-title":"Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy","volume":"95","author":"KA Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ijrobp.2015.01.036","article-title":"Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection","volume":"92","author":"KA Ahmed","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/1078-0432.CCR-08-0358","article-title":"An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease","volume":"14","author":"JK Salama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial","volume":"9","author":"J Kao","year":"2014","journal-title":"Target Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"P Therasse","year":"2000","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"ref31","unstructured":"Hong JC. julianhong\/oligometastasis. In: github.com [Internet]. [cited 20 Mar 2018]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/github.com\/julianhong\/oligometastasis\" xlink:type=\"simple\">https:\/\/github.com\/julianhong\/oligometastasis<\/ext-link>"},{"key":"ref32","article-title":"Classification and Regression Trees","author":"L Breiman","year":"1984"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"RJ Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"RJ Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"KS Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-7-148","article-title":"Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors","volume":"7","author":"M-AS Kress","year":"2012","journal-title":"Radiat Oncol. BioMed Central"},{"key":"ref37","article-title":"198PD: Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation","author":"M Guckenberger","year":"2016","journal-title":"Journal of Thoracic \u2026"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"AB Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"MM Fode","year":"2015","journal-title":"Radiother Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.04.012","article-title":"Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group &quot;stereotactic radiotherapy&quot;","volume":"97","author":"J Rieber","year":"2016","journal-title":"Lung Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijrobp.2016.09.026","article-title":"Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease","volume":"98","author":"J Rieber","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease\u2014Influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"RJ Klement","year":"2017","journal-title":"Radiother Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2013.07.023","article-title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors","volume":"82","author":"GHMJ Griffioen","year":"2013","journal-title":"Lung Cancer"},{"key":"ref44","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","author":"DR Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3501","article-title":"Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)","volume":"33","author":"T Ruers","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijrobp.2016.01.020","article-title":"Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases","volume":"95","author":"NH Lester-Coll","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/0284186X.2015.1118659","article-title":"A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up","volume":"55","author":"R Dagan","year":"2016","journal-title":"Acta Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1471-2407-12-305","article-title":"Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial","volume":"12","author":"DA Palma","year":"2012","journal-title":"BMC Cancer"},{"key":"ref49","unstructured":"A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases [Internet]. [cited 1 Jul 2016]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02206334\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02206334<\/ext-link>"},{"key":"ref50","unstructured":"A Phase IIR\/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and\/or Surgical Ablation for Newly Oligometastatic Breast Cancer. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02364557\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02364557<\/ext-link>"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0195149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T06:48:50Z","timestamp":1571122130000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0195149"}},"subtitle":[],"editor":[{"given":"Piet","family":"Ost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0195149","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]}}}